STSoichiro Tsuda

Soichiro Tsuda

*This is an algorithmically generated author record based on publicly available information.

Soichiro Tsuda has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Combination of Two‐Enzyme System and Enzyme Engineering Improved the Activity of a New PET Hydrolase Identified from Soil Bacterial Genome

    by Hideaki Mabashi‐Asazuma, Makoto Hirai, Shigeru Sakurai, Keigo Ide, Masato Kogawa, Ai Matsushita, Masahito Hosokawa, Soichiro Tsuda

    We here report a novel PET hydrolase originating from a soil microbial genome sequence. This enzyme, bbPET0069, exhibits characteristics resembling a cutinase‐like Type I PET‐degrading enzyme but lacks disulfide bonds. Notably, bbPET0069 displayed remarkable synergy with Candida antarctica lipase B (CALB), demonstrating rapid and efficient PET degradation. To improve the PET degradation activity of bbPET0069, we employed a 3D structural modeling to identify mutation sites around its substrate binding domain combined with a protein language model for effective mutation prediction. Through three initial rounds of directed evolution, we achieved a significant enhancement in PET degradation with CALB, resulting in a 12.6‐fold increase compared to wild‐type bbPET0069 without CALB. We confirmed its PET degradation activity in PET nanoparticles and films, and our proposed approach enabled efficient PET degradation to terephthalic acid monomers up to 95.5%. Our approach, which integrates a two‐enzyme system with protein engineering, demonstrates the potential for enhancing the activity of emerging PET‐degradation enzymes, which may possess unique attributes.


  • Open Access

    Development of Chimera AMP–Endolysin with Wider Spectra Against Gram-Negative Bacteria Using High-Throughput Assay

    by Masato Kogawa, Takuya Yoda, Ayumi Matsuhashi, Ai Matsushita, Yoshiki Otsuka, Shohei Shibagaki, Masahito Hosokawa, Soichiro Tsuda

    Bacteriophage-derived endolysins are being developed as an alternative to antimicrobials. The development of endolysins against Gram-negative bacteria requires the discovery of effective endolysins against the target species and the capability to penetrate the outer membrane of bacteria by endolysin. Here, we propose an efficient endolysin development approach that combines a data-driven endolysin search utilizing bacterial genomes with high-throughput laboratory assays. As a proof of concept, we analyzed endolysin genes detected in 273 bacterial genomes of Acinetobacter, Pseudomonas, and Escherichia. Firstly, we conducted assays of 192 recombinants of endolysin genes obtained through in silico search from bacterial genomes and identified natural endolysins degrading peptidoglycan of Acinetobacter baumannii. Then, we performed high-throughput screening against Gram-negative bacteria for hundreds of chimera AMP–endolysins, natural endolysin conjugated with antimicrobial peptide. As a result, we obtained four chimera AMP–endolysins against A. baumannii, which demonstrated the minimum inhibitory concentration ranging from 4 to 8 μg/mL. Moreover, we assessed the antimicrobial spectra of these chimera AMP–endolysins, validating that two endolysins exhibited antimicrobial efficacy against Pseudomonas aeruginosa and Escherichia coli with <32 μg/mL of concentration. This endolysin development approach can be applied to other Gram-negative bacterial targets and is expected to facilitate the acquisition of effective novel endolysins.


  • Open Access

    Uncovering Endolysins against Methicillin-Resistant Staphylococcus aureus Using a Microbial Single-Cell Genome Database

    by Takuya Yoda, Ayumi Matsuhashi, Ai Matsushita, Shohei Shibagaki, Yukie Sasakura, Kazuteru Aoki, Masahito Hosokawa, Soichiro Tsuda

    Endolysins, peptidoglycan hydrolases derived from bacteriophages (phages), are being developed as a promising alternative to conventional antibiotics. To obtain highly active endolysins, a diverse library of these endolysins is vital. We propose here microbial single-cell genome sequencing as an efficient tool to discover dozens of previously unknown endolysins, owing to its culture-independent sequencing method. As a proof of concept, we analyzed and recovered endolysin genes within prophage regions of Staphylococcus single-amplified genomes in human skin microbiome samples. We constructed a library of chimeric endolysins by shuffling domains of the natural endolysins and performed high-throughput screening against Staphylococcus aureus. One of the lead endolysins, bbst1027, exhibited desirable antimicrobial properties, such as rapid bactericidal activity, no detectable resistance development, and in vivo efficacy. We foresee that this endolysin discovery pipeline is in principle applicable to any bacterial target and boost the development of novel antimicrobial agents.


  • Open Access

    A combination of two-enzyme system and enzyme engineering improved the activity of a new PET hydrolase identified from soil bacterial genome

    by Hideaki Mabashi-Asazuma, Makoto Hirai, Shigeru Sakurai, Keigo Ide, Masato Kogawa, Ai Matsushita, Masahito Hosokawa, Soichiro Tsuda

    We here report a novel PET hydrolase originating from a soil microbial genome sequence. This enzyme, bbPET0069, exhibits characteristics resembling a cutinase-like Type I PET-degrading enzyme but lacks disulfide bonds. Notably, bbPET0069 displayed remarkable synergy with Candida antarctica lipase B (CALB), demonstrating rapid and efficient PET degradation. To improve the PET degradation activity of bbPET0069, we employed a three-dimensional (3D) structural modeling to identify mutation sites around its substrate binding domain combined with a protein language model for effective mutation prediction. Through three initial rounds of directed evolution, we achieved a significant enhancement in PET degradation with CALB, resulting in a 12.6-fold increase compared to wild-type bbPET0069 without CALB. We confirmed its PET degradation activity in PET nanoparticles and films, and our proposed approach enabled efficient PET degradation to terephthalic acid monomers up to 95.5%. Our approach, which integrates a two-enzyme system with protein engineering, demonstrates the potential for enhancing the activity of emerging PET-degradation enzymes, which may possess unique attributes. Graphical A novel PET hydrolase, bbPET0069, was identified from a soil microbial genome. bbPET0069 and CALB showed remarkable synergy in PET degradation. Using surface feature analysis, PET degradation activity of bbPET0069 was significantly improved. This combination of a two-enzyme system and surface feature analysis holds promise for enhancing emerging PET-degradation enzymes.


  • Open Access

    Uncovering novel endolysins against methicillin-resistant Staphylococcus aureus using microbial single-cell genome sequencing

    by Takuya Yoda, Ayumi Matsuhashi, Ai Matsushita, Shohei Shibagaki, Yukie Sasakura, Kazuteru Aoki, Masahito Hosokawa, Soichiro Tsuda

    Endolysins, peptidoglycan hydrolases derived from bacteriophages (phages), are being developed as a promising alternative to conventional antibiotics. To obtain highly active endolysins, a diverse library of endolysins is vital. We here propose microbial single-cell genome sequencing as an efficient tool to discover dozens of previously unknown endolysins, owing to its culture-independent sequencing method. As a proof-of-concept, we analyzed and recovered endolysin genes within prophage regions of Staphylococcus single-amplified genomes (SAGs) in human skin microbiome samples. We constructed a library of chimeric endolysins by shuffling domains of the natural endolysins and performed high-throughput screening against Staphylococcus aureus . One of the lead endolysins, bbst1027, exhibited desirable antimicrobial properties such as rapid bactericidal activity, no detectable resistance development, and in vivo efficacy. We foresee that this endolysin discovery pipeline is in principle applicable to any bacterial target, and boost the development of novel antimicrobial agents.


  • Target enrichment of uncultured human oral bacteria with phage-derived molecules found by single-cell genomics

    by Masahito Hosokawa, Naoya Iwai, Koji Arikawa, Tatsuya Saeki, Taruho Endoh, Kazuma Kamata, Takuya Yoda, Soichiro Tsuda, Haruko Takeyama


  • Open Access

    Establishment of a novel method for the production of chimeric mouse embryos using water-in-oil droplets

    by Hiroyuki Imai, Soichiro Tsuda, Tokuko Iwamori, Kiyoshi Kano, Ken Takeshi Kusakabe, Etsuro Ono

    Production of chimeric animals is often a necessity for the generation of genetically modified animals and has gained popularity in recent years in regenerative medicine for the reconstruction of xenogeneic organs. Aggregation and injection methods are generally used to produce chimeric mice. In the aggregation method, the chimeras are produced by co-culturing embryos and stem cells, and keeping them physically adhered, although it may not be an assured method for producing chimeric embryos. In the injection method, the chimeras are produced by injecting stem cells into the zona pellucida using microcapillaries; however, this technique requires a high degree of skill. This study aimed to establish a novel method for producing chimeric embryos via water-in-oil droplets that differs from conventional methods. In this study, embryonic stem cells and embryos were successfully isolated in the droplets, and the emergence of chimeric embryos was confirmed by co-culture for 6 h. Using this method, the control and operability of stem cell numbers could be regulated, and reproducibility and quantification were improved during the production of chimeric embryos. In addition to the conventional methods for producing chimeric embryos, the novel method described here could be employed for the efficient production of chimeric animals.


  • Open Access

    High-throughput screening of high protein producer budding yeast using gel microdrop technology

    by Hirotsugu Fujitani, Soichiro Tsuda, Tomoko Ishii, Masayuki Machida

    The need for protein production has been growing over the years in various industries. We here present a high-throughput screening strategy to isolate high producer budding yeast clones from a mutagenized cell population using gel microdrop (GMD) technology. We use a microfluidic water-in-oil (W/O) emulsion method to produce monodisperse GMDs and a microfluidic cell sorter for damage-free sorting of GMDs by fluorescently quantifying secreted proteins. As a result, this high-throughput GMD screening method effectively selects high producer clones and improves protein production up to five-fold. We speculate that this screening strategy can be applied, in principle, to select any types of high producer cells (bacterial, fungal, mammalian, etc.) which produce arbitrary target protein as it does not depend on enzymes to be produced.


  • Open Access

    Effects of Co-administration of Proton Pump Inhibitors on Methotrexate Elimination and Adverse Events

    by Keisuke Kiyomiya, Soichiro Tsuda, Jun Hakamada, Takehiko Mori, Takayuki Shimizu, Jun Kato, Taku Kikuchi, Masatoshi Sakurai, Yuya Koda, Mayumi Mochizuki

    Co-administration of methotrexate (MTX) and proton pump inhibitors (PPIs) is reported to increase serum MTX concentrations in patients receiving high-dose MTX therapy. However, the range of MTX high dosage is wide. We attempted to clarify the effects of PPIs co-administration on the elimination of MTX at the fixed dose of 1 g/m2 in a retrospective cohort study of 46 patients with hematological malignancies who underwent a total of 91 cycles of chemotherapy. Data on gender, age, concomitant drugs, and laboratory test results were analyzed. The median and first to third quartile of MTX concentrations with and without PPI co-administration at 24, 48, and 72 h postdosing were 17.42 (14.75 - 22.34) vs 19.96 (14.97 - 23.10) (P = 0.627), 0.25 (0.15 - 0.42) vs 0.34 (0.17 - 0.96) (P = 0.159), and 0.06 (0.04 - 0.10) vs 0.07 (0.04 - 0.23) (P = 0.357), respectively. No statistically significant differences were observed in the number of patients with delayed MTX elimination with each PPI. Nausea (all grades) was significantly less frequent in patients receiving PPIs (38% with vs 68% without, P < 0.05). Multivariate analysis results indicated that differences in creatinine clearance (24 h after MTX administration and baseline) (OR, 0.92; 95%CI, 0.88 - 0.97), gender (OR, 4.95; 95%CI, 1.55 - 15.81), and age (OR, 1.04; 95%CI, 1.00 - 1.08) were risk factors for delayed MTX elimination. These findings suggest that PPI co-administration does not affect MTX elimination at the dose of 1 g/m2, but could relief nausea associated with chemotherapy.

  • Open Access

    Uncovering cell-free protein expression dynamics by a promoter library with diverse strengths

    by Sabrina Galiñanes Reyes, Yutetsu Kuruma, Soichiro Tsuda

    Cell-free protein expression systems have been widely used for synthetic biology and metabolic engineering applications in recent years. Yet little is known about protein expression in the cell-free systems. Here we take a systems approach to uncover underlying dynamics of cell-free protein expression. We construct a set of T7 promoter variants to express proteins at different transcription rates in a reconstituted and E. coli extract-based cell-free systems. We find that the maximum expression level and the rate of protein synthesis as responses to the transcription rate change are different in the two cell-free systems, suggesting they are driven by different expression dynamics. We confirm this by constructing a simple mathematical model for each cell-free system, which well reproduce the experimental results and also identify different limiting factors for better protein expression in the two cell-free systems. In particular, they revealed there is a negative feedback effect in the mRNA-protein translation by the PURE system and also identified different limiting factors for better protein expression in the two cell-free systems.